

Client: Example Client ABC123 123 Test Drive Salt Lake City, UT 84108 UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB	6/25/1996
Gender:	Female
Patient Identifiers:	01234567890ABCD, 012345
Visit Number (FIN):	01234567890ABCD
Collection Date:	00/00/0000 00:00

Hypoglycemia Panel (Sulfonylureas), Serum or Plasma

ARUP test code 3005636

Rosiglitazone	None Det ng/mL Serum or Plasma Reporting Limit: 40 ng/mL				
	Synonym(s): Avandia(R); Avandaryl(R); Avandamet(R) Peak plasma concentrations of approximately 70-430 ng/mL and 240-830 ng/mL were achieved 1 hour after administration of 4 mg and 8 mg daily doses, respectively. Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS)				
Chlorpropamide	None Det mcg/mL Serum or Plasma Reporting Limit: 0.10 mcg/mL				
	Synonym(s): Diabinese(R) Peak plasma concentrations of approximately 75-360 mcg/mL were achieved 2 hours following chronic daily doses of 250-1000 mg. The blood to plasma ratio of Chlorpropamide is not known. Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS)				
Glimepiride	None Det ng/mL				
	Serum or Plasma Reporting Limit: 25 ng/mL				
	Synonym(s): Duetact(R); Avandaryl(R); Amaryl(R) Peak plasma concentrations of approximately 60-340 ng/mL were achieved 2-3 hours after administration of 4 mg of glimepiride. The blood to plasma ratio of Glimepiride is not known. Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS)				
Glipizide	None Det ng/mL				
H=High, L=Low, *=Abnormal, C=Critical					

Unless otherwise indicated, testing performed at:



Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com 500 Chipeta Way, Salt Lake City, UT 84108-1221 Jonathan R. Genzen, MD, PhD, Laboratory Director



H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com 500 Chipeta Way, Salt Lake City, UT 84108-1221 Jonathan R. Genzen, MD, PhD, Laboratory Director



VERIFIED/REPORTED DATES					
Procedure	Accession	Collected	Received	Verified/Reported	
Rosiglitazone	24-163-134279	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00	
Chlorpropamide	24-163-134279	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00	
Glimepiride	24-163-134279	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00	
Glipizide	24-163-134279	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00	
Pioglitazone	24-163-134279	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00	
Glyburide	24-163-134279	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00	
Nateglinide	24-163-134279	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00	
Tolazamide	24-163-134279	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00	
Tolbutamide	24-163-134279	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00	
Repaglinide	24-163-134279	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00	

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com 500 Chipeta Way, Salt Lake City, UT 84108-1221 Jonathan R. Genzen, MD, PhD, Laboratory Director